Efficacy and safety of a new intradermal PCV2 vaccine in pigs

The safety and efficacy of a new intradermal one dose vaccine containing Porcine Circovirus type 2 (PCV2) antigen – Porcilis® PCV ID – was evaluated in laboratory studies and under field conditions. In addition, the concurrent use with an intradermal Mycoplasma hyopneumoniae vaccine – Porcilis® M Hyo ID ONCE – was evaluated.Vaccination with Porcilis® PCV ID resulted in small transient local reactions in a high percentage of the vaccinated animals with no temperature increase. In both the onset of immunity and duration of immunity challenge studies with PCV2 or M. hyopneumoniae, significant reduction of the PCV2 load in lymphoid tissue, lungs, serum and fecal swabs and M. hyopneumoniae-induced lung lesions were observed. In two field trials on two different farms where both PCV2 and M. hyopneumoniae were present, vaccination with Porcilis® PCV ID and/or Porcilis® M Hyo ID ONCE of 3 week old piglets resulted in a significant reduction of PCV2 viraemia, mortality and lung lesion scores at slaughter. In addition, a significant positive effect on average daily weight gain (between 44 and 59 g/day) in the finishing phase was observed. The results support that this new intradermal vaccine is safe and efficacious against PCV2 and may be used concurrently with Porcilis® M Hyo ID ONCE.